GPNMB: a potent inducer of immunosuppression in cancer

Oncogene. 2022 Oct;41(41):4573-4590. doi: 10.1038/s41388-022-02443-2. Epub 2022 Sep 1.

Abstract

The immune system is comprised of both innate and adaptive immune cells, which, in the context of cancer, collectively function to eliminate tumor cells. However, tumors can actively sculpt the immune landscape to favor the establishment of an immunosuppressive microenvironment, which promotes tumor growth and progression to metastatic disease. Glycoprotein-NMB (GPNMB) is a transmembrane glycoprotein that is overexpressed in a variety of cancers. It can promote primary tumor growth and metastasis, and GPNMB expression correlates with poor prognosis and shorter recurrence-free survival in patients. There is growing evidence supporting an immunosuppressive role for GPNMB in the context of malignancy. This review provides a description of the emerging roles of GPNMB as an inducer of immunosuppression, with a particular focus on its role in mediating cancer progression by restraining pro-inflammatory innate and adaptive immune responses.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunosuppression Therapy
  • Membrane Glycoproteins* / genetics
  • Membrane Glycoproteins* / metabolism
  • Neoplasms* / genetics
  • Neoplasms* / metabolism
  • Tumor Microenvironment

Substances

  • GPNMB protein, human
  • Membrane Glycoproteins

Grants and funding